The brown adipocyte protein CIDEA promotes lipid droplet fusion via a phosphatidic acid-binding amphipathic helix

  1. David Barneda
  2. Joan Planas-Iglesias
  3. Maria L Gaspar
  4. Dariush Mohammadyani
  5. Sunil Prasannan
  6. Dirk Dormann
  7. Gil-Soo Han
  8. Stephen A Jesch
  9. George M Carman
  10. Valerian Kagan
  11. Malcolm G Parker
  12. Nicholas T Ktistakis
  13. Ann M Dixon
  14. Judith Klein-Seetharaman
  15. Susan Henry
  16. Mark Christian  Is a corresponding author
  1. Imperial College London, United Kingdom
  2. University of Warwick, United Kingdom
  3. Cornell University, United States
  4. University of Pittsburgh, United States
  5. Imperial College London, United States
  6. Rutgers University, United States
  7. Babraham Institute, United Kingdom

Abstract

Maintenance of energy homeostasis depends on the highly regulated storage and release of triacylglycerol primarily in adipose tissue and excessive storage is a feature of common metabolic disorders. CIDEA is a lipid droplet (LD)-protein enriched in brown adipocytes promoting the enlargement of LDs which are dynamic, ubiquitous organelles specialized for storing neutral lipids. We demonstrate an essential role in this process for an amphipathic helix in CIDEA, which facilitates embedding in the LD phospholipid monolayer and binds phosphatidic acid (PA). LD pairs are docked by CIDEA trans-complexes through contributions of the N-terminal domain and a C-terminal dimerization region. These complexes, enriched at the LD-LD contact site, interact with the cone-shaped phospholipid PA and likely increase phospholipid barrier permeability, promoting LD fusion by transference of lipids. This physiological process is essential in adipocyte differentiation as well as serving to facilitate the tight coupling of lipolysis and lipogenesis in activated brown fat.

Article and author information

Author details

  1. David Barneda

    Institute of Reproductive and Developmental Biology, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Joan Planas-Iglesias

    Warwick Medical School, University of Warwick, Coventry, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Maria L Gaspar

    Department of Molecular Biology and Genetics, Cornell University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Dariush Mohammadyani

    Department of Bioengineering, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Sunil Prasannan

    Department of Chemistry, University of Warwick, Coventry, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Dirk Dormann

    Microscopy Facility, MRC Clinical Sciences Centre, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Gil-Soo Han

    Microscopy Facility, MRC Clinical Sciences Centre, Imperial College London, London, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Stephen A Jesch

    Department of Molecular Biology and Genetics, Cornell University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. George M Carman

    Department of Food Science, Rutgers Center for Lipid Research, Rutgers University, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Valerian Kagan

    Department of Bioengineering, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Malcolm G Parker

    Institute of Reproductive and Developmental Biology, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Nicholas T Ktistakis

    Signalling Programme, Babraham Institute, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Ann M Dixon

    Department of Chemistry, University of Warwick, Coventry, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  14. Judith Klein-Seetharaman

    Warwick Medical School, University of Warwick, Coventry, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Susan Henry

    Department of Molecular Biology and Genetics, Cornell University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Mark Christian

    Institute of Reproductive and Developmental Biology, Imperial College London, London, United Kingdom
    For correspondence
    m.christian@warwick.ac.uk
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Stephen G Young, University of California, Los Angeles, United States

Version history

  1. Received: March 13, 2015
  2. Accepted: November 25, 2015
  3. Accepted Manuscript published: November 26, 2015 (version 1)
  4. Accepted Manuscript updated: December 10, 2015 (version 2)
  5. Version of Record published: February 3, 2016 (version 3)

Copyright

© 2015, Barneda et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,336
    views
  • 1,169
    downloads
  • 107
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David Barneda
  2. Joan Planas-Iglesias
  3. Maria L Gaspar
  4. Dariush Mohammadyani
  5. Sunil Prasannan
  6. Dirk Dormann
  7. Gil-Soo Han
  8. Stephen A Jesch
  9. George M Carman
  10. Valerian Kagan
  11. Malcolm G Parker
  12. Nicholas T Ktistakis
  13. Ann M Dixon
  14. Judith Klein-Seetharaman
  15. Susan Henry
  16. Mark Christian
(2015)
The brown adipocyte protein CIDEA promotes lipid droplet fusion via a phosphatidic acid-binding amphipathic helix
eLife 4:e07485.
https://doi.org/10.7554/eLife.07485

Share this article

https://doi.org/10.7554/eLife.07485

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Damien M Rasmussen, Manny M Semonis ... Nicholas M Levinson
    Research Article

    The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.

    1. Structural Biology and Molecular Biophysics
    Nicholas James Ose, Paul Campitelli ... Sefika Banu Ozkan
    Research Article

    We integrate evolutionary predictions based on the neutral theory of molecular evolution with protein dynamics to generate mechanistic insight into the molecular adaptations of the SARS-COV-2 spike (S) protein. With this approach, we first identified candidate adaptive polymorphisms (CAPs) of the SARS-CoV-2 S protein and assessed the impact of these CAPs through dynamics analysis. Not only have we found that CAPs frequently overlap with well-known functional sites, but also, using several different dynamics-based metrics, we reveal the critical allosteric interplay between SARS-CoV-2 CAPs and the S protein binding sites with the human ACE2 (hACE2) protein. CAPs interact far differently with the hACE2 binding site residues in the open conformation of the S protein compared to the closed form. In particular, the CAP sites control the dynamics of binding residues in the open state, suggesting an allosteric control of hACE2 binding. We also explored the characteristic mutations of different SARS-CoV-2 strains to find dynamic hallmarks and potential effects of future mutations. Our analyses reveal that Delta strain-specific variants have non-additive (i.e., epistatic) interactions with CAP sites, whereas the less pathogenic Omicron strains have mostly additive mutations. Finally, our dynamics-based analysis suggests that the novel mutations observed in the Omicron strain epistatically interact with the CAP sites to help escape antibody binding.